Clinical trials: Fasting Glucose
Non-Insulin-dependent Diabetes Mellitus
Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects
A double-blind, randomized, placebo-controlled, multi-dose clinical study consisting of 2 phases; 1) an 8-week lead-in period during which patients followed a diet judged to be within the acceptable guidelines of the ADA, and 2)…
- Trial name
- NCT01582282
- Testing
- 3.4 g psyllium BID, 6.8g psyllium BID
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Procter and Gamble
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes
The purpose of the study is to evaluate the efficacy and safety of vildagliptin 50 mg bid as an add-on therapy to metformin in Japanese patients with T2DM.
- Trial name
- NCT01497522
- Testing
- Vildagliptin
- Where
- 20 sites in Japan
- Volunteers
- 183 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers
This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetics and safety of CKD-383 in healthy volunteers.
- Trial name
- NCT07304700
- Testing
- CKD-383 0.5/10/1000mg, CKD-501, D744, D150
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus
Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics
The aim of this study is to examine the effects of ISIS 113715 monotherapy on insulin sensitivity, glucose and lipid metabolism and energy expenditure in subjects with type 2 diabetes mellitus.
- Trial name
- NCT00330200
- Testing
- ISIS 113715
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Prediabetes
Trial of an Herb and Mineral Combination Product on Fasting Glucose in Adults at Risk for Developing Diabetes
This is a multi-center, randomized, double-blind, placebo-controlled study in approximately 104 subjects (52 per group) to evaluate the effectiveness of an herb and mineral combination product on fasting serum glucose levels in…
- Trial name
- NCT02146157
- Testing
- herb and mineral combination product
- Where
- 6 sites in United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- NewChapter, Inc.
Diabetes, Diabetes Mellitus, Type 2
Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily
This trial is conducted in the United States of America. The aim of this trial is to explore how different fasting blood glucose targets affect glucose control in patients with type 2 diabetes, when patients are empowered to do…
- Trial name
- TITRATE™ (NCT00634842)
- Testing
- insulin detemir
- Where
- 69 sites in United States, Puerto Rico
- Volunteers
- 244 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Bioequivalence Study to Compare Imeglimin HCl 500 mg Film Coated Tablets Versus Twymeeg Tablets 500 mg
An Open Label, Balanced, Randomized, Single dose, Two treatment, Two sequence, Two period, Two way crossover, Oral Bioequivalence Study of Imeglimin HCl 500 mg Film Coated Tablets of Humanis Sağlık A.Ş., Ç.O.S.B.
- Trial name
- NCT07691177
- Testing
- Imeglimin Hydrochloride Film Coated Tablet, TWYMEEG® Tablets
- Where
- India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Prediabetic State
Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes
Primary objective: To evaluate the effect of long-term administration of Rimonabant on the time of progression to type 2 diabetes in patients with prediabetes (i.e.
- Trial name
- RAPSODI (NCT00325650)
- Testing
- Rimonabant
- Where
- United States
- Volunteers
- 2,420 people
- Sponsor
- Sanofi
Diabetes Mellitus
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)
This was an open-label, randomized, fasting, single-dose, 2-sequence, 2-period crossover study to evaluate the pharmacokinetics and safety between single oral administration of "BR3006" and co-administration of "BR3006A"…
- Trial name
- NCT07083388
- Testing
- Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg, Dapagliflozin 10 mg, Pioglitazone 30 mg
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetes Mellitus
A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232
A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232
- Trial name
- NCT07538466
- Testing
- AD-123, AD-1231 and AD-1232
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Effects of Different Meals on the QT/QTc Interval, Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use
Food and Insulin Effect on QT/QTC Interval of ECG
Moxifloxacin is routinely used as a probe to confirm assay sensitivity in thorough electrocardiogram (ECG) studies. It has been shown that a meal shortens the QT interval, which may affect pharmacokinetics (PK) and/or…
- Conditions
- Effects of Different Meals on the QT/QTc Interval, Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use, C-Peptide Effects on the QT/QTc Interval, Moxifloxacin ECG Profile in Fed and Fasted State
- Trial name
- C11035 (NCT01642485)
- Testing
- Moxifloxacin 400 mg fasted, FDA breakfast, Continental breakfast
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Richmond Pharmacology Limited
Type 2 Diabetes
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers
This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetics and safety of CKD-383 in healthy volunteers
- Trial name
- NCT07304726
- Testing
- CKD-383 0.25/12.5/1000mg, CKD-501, D745, D150
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Bioequivalence, Fixed Dose Combination Tablets
A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects
This is a bioequivalence study to compare 2 fixed-dose combination tablets of dapagliflozin/metformin XR manufactured at 2 different plants in healthy subjects under fasting and fed conditions
- Conditions
- Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
- Trial name
- NCT02637037
- Testing
- dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
SAM - Skip a Meal - Insulin Glargine, Diabetes Mellitus Type 1
Primary objective: To compare metabolic control as measured by Blood Glucose (BG) upon arising from bed (7:00 am - 12:00 pm) in type 1 Diabetes mellitus patients who skip the morning meal during treatment with MDI basal/bolus…
- Trial name
- NCT00313937
- Testing
- Insulin glargine
- Where
- Germany
- Volunteers
- 91 people
- Sponsor
- Sanofi
Type 2 Diabetes
Observational Study of Effectiveness and Tolerability of Gliclazide MR 60mg in Diabetic Patients Fasting During RAMADAN
The purpose of this observational study is to assess effectiveness and tolerability of gliclazide MR 60mg during RAMADAN in a real world setting in 9 countries from Asia Pacific and Middle East/North Africa
- Trial name
- DIA-RAMADAN (NCT04132934)
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Servier Affaires Médicales
Diabetes Mellitus, Type 2, Overweight
A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus
The purpose of this study is to evaluate how fasting and stopping the use of tirzepatide affects the amount of food and drink that stays in the stomach after a meal.
- Conditions
- Diabetes Mellitus, Type 2, Overweight, Obesity
- Trial name
- NCT07299084
- Testing
- Tirzepatide
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Eli Lilly and Company
PreDiabetes
To Evaluate the Impact of Consumption of a Bioactive Compound on Fasting Blood Glucose Levels in Asian Indians With Pre-diabetes
This is randomized placebo controlled, double-blinded, parallel arm study on free living Asian Indians. Eligible subjects will undergo one-week run-in period and subjects will be asked to maintain their usual diet and exercise…
- Trial name
- NCT06417840
- Testing
- N-trans-caffeoyltyramine (NCT) and N-trans-feruloyltyramine (NFT)
- Where
- India
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Brightseed
Prediabetes, Hypertension
Fasting Predictors of OGTT and MMTT Response
1. To develop a database containing matched information from dynamic tests of postprandial glycemic control (OGTT or MMTT), results of a broad panel of fasting biomarkers, and clinical information related to diabetes risk obtain…
- Conditions
- Prediabetes, Hypertension, Obesity, Cardiovascular Disease
- Trial name
- NCT01998867
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Health Diagnostic Laboratory, Inc.
Diabetes Mellitus, Type 1
A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus
This study is looking at how five different formulations of faster aspart 200 U/mL reach and stay in the blood after injection. The purpose is to find a formulation that behaves similarly to the reference product called faster…
- Trial name
- NCT03723759
- Testing
- Faster Aspart 200 U/mL, Faster aspart 100 U/mL
- Where
- Germany
- Volunteers
- 56 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus
Phase 1 Study in Diabetes Mellitus(Fasting)
An open-label, randomized, fasting, single-dose, 2-sequence, 2-period, crossover phase 1 study in healthy volunteers.
- Trial name
- NCT06552182
- Testing
- HUC2-344, HUC2-344-R1, HUC2-344-R2
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.